Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
All PLHIV pictured and quoted in this website have been prescribed every-2-month VOCABRIA + REKAMBYS. They have given consent for the use of their images and words, and have received remuneration from ViiV Healthcare.
Indication: VOCABRIA injection is indicated, in combination with REKAMBYS injection, for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.1,2
Long-Acting ARVs: A tool for addressing the mental health impact of living with HIV
Vocabria▼ + Rekambys▼ - Abbreviated Prescribing Information
POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
PM-IE-CBR-WCNT-230009 | Date of Preparation: October 2023
INTRODUCING SOLAR
The first head-to-head switch study comparing every-2-month VOCABRIA + REKAMBYS with daily oral therapy3
SOLAR investigated the efficacy, safety and treatment experience of participants who were switched to every-2-month VOCABRIA + REKAMBYS (n=454) vs those who continued daily oral therapy with BIC/FTC/TAF (n=227).3
The SOLAR primary endpoint was met: Every-2-month VOCABRIA + REKAMBYS was virologically non-inferior to daily oral therapy with BIC/FTC/TAF at Month 12 (modified intention-to-treat exposed [mITT-E]: 1.1% [n=5/447] with plasma HIV-1 RNA ≥50 copies/mL vs 0.4% [n=1/223], respectively, adjusted difference = 0.7% [95% CI -0.7%, 2.0%]).3
THE ONLY COMPLETE LONG-ACTING REGIMEN FOR HIV-1 TREATMENT
*Two months between doses is on the continuation phase of treatment.
BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; CI=confidence interval; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; INI=integrase inhibitor; mITT-E=modified intention-to-treat exposed; NNRTI=non-nucleoside reverse transcriptase inhibitor; PLHIV=people living with HIV; RNA=ribonucleic acid.
- VOCABRIA Summary of Product Characteristics. ViiV Healthcare; 2023. Available at: https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc#tabs [Last Accessed: January 2024]
- REKAMBYS Summary of Product Characteristics. Janssen-Cilag International NV; 2023. Available at: https://www.medicines.ie/medicines/rekambys-35258/spc [Last Accessed: January 2024]
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. The Lancet HIV. 2023. Published Online 8th August 2023. https://doi.org/10.1016/S2352-3018(23)00136-4
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.
All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2024 GSK group of companies. All rights reserved.
PM-IE-CBR-WCNT-230010
Date of preparation: January 2024
